Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.

Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA

FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S.

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

COMPASS Pathways

Their low price tags belie their massive long-term potential.

2 No-Brainer Stocks to Buy Right Now for Less Than $15

Aerie Pharmaceuticals

Belite Bio Inc

Chemocentryx

Verona Pharma

Akero Therapeutics Inc

Gossamer Bio Inc

Relmada Therapeutics Inc

Viridian Therapeutics

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

Looking for a Growth Stock? 3 Reasons Why Catalyst (CPRX) is a Solid Choice

Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Catalyst (CPRX) Upgraded to Buy: Here's What You Should Know

BioMarin Pharmaceutical

Neurocrine Biosciences

Vertex Pharmaceuticals

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

Here is how Catalyst Pharmaceutical (CPRX) and Lyell Immunopharma (LYEL) have performed compared to their sector so far this year.

Is Catalyst Pharmaceuticals (CPRX) Outperforming Other Medical Stocks This Year?

Catalyst Pharmaceuticals reached a 52-week high on September 13, 2022. Catalyst was recently added to the S&P SmallCap 600 Index.

Catalyst Pharmaceuticals Ramp May Be Over For Now

Albemarle

Some companies can stand up to tough conditions on Wall Street.

As Markets Plunged, These 2 Stocks Hit All-Time Highs

Teekay Tankers

Both are in buy zones after topping follow-on patterns. The post Biotech, Tanker Stocks Hit New Highs, Top Bullish Patterns appeared first on Investor's Business Daily.

Biotech, Tanker Stocks Hit New Highs, Top Bullish Patterns

This supercharged growth stock posted a new all-time high this week.

Why Catalyst Pharmaceuticals Stock Marched Higher This Week

AVEO Pharma

Tsakos Energy Navigation Limited

Tsakos Energy Navigation (TNP), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX) have been selected as the breakout stocks for today.

Buy These 3 Top Breakout Stocks Now for Superb Returns

CORAL GABLES, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate in the hybrid in-person and virtual H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022.

Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?

Pharmaceuticals stock is trading above a 3-week base on heavy volume. The company is first in its industry.

Pharmaceuticals Stock Clears A Base Following Two Prior Gap-Ups

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Catalyst Pharmaceutical (CPRX) Just Reclaimed the 20-Day Moving Average

Veru

Their recent successes with commercializing medicines are paying off.

Got $1,500? Buy These 2 Surging Growth Stocks

Catalyst Pharmaceuticals is now looking for its second act after launching a LEMS treatment. Could CPRX stock investors see a buyout?

Catalyst Pharmaceuticals' CEO Wants In On The Biotech Buying Spree

3 Reasons Why Catalyst (CPRX) Is a Great Growth Stock

Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock to Buy

CORAL GABLES, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Citi's 17th Annual BioPharma Conference.

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

It might not last forever, but for now they're preparing to grow aggressively.

Got $2,500? These 2 Small-Cap Monsters Are Crushing Tesla Stock

Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.

Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up

Start Time: 08:30 January 1, 0000 9:12 AM ET Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2022 Earnings Conference Call August 10, 2022, 08:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman, President and CEO Jeff Del Carmen - Chief Commercial Officer Steven Miller - COO and Chief Scientific Officer Ali Grande - VP, CFO and Treasurer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joe Catanzaro - Piper Sandler Les Sulewski - Truist Securities Operator Greetings, and welcome to the Catalyst Pharmaceuticals Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

News for Catalyst Pharmaceuticals Stock (CPRX)